Several other strategies have been evaluated, and recently, the combination of antiangiogenic therapy targeting VEGF (bevacizumab) with the immune checkpoint inhibitor anti-PD-L1 (atezolizumab) was demonstrated to be superior to sorafenib in terms of tumor response and survival benefit [23,90]. The gene discussed is VEGFA; the disease is neoplasm.